BURNABY, BC, April 8 /CNW/ - Welichem Biotech Inc. ("Welichem" or the "Company") (TSX-V: WBI) announces that the Company held its special meeting of shareholders (the "Special Meeting") on Monday, April 6, 2009. The Company's shareholders passed a special resolution to approve the proposed consolidation of all of the Company's issued and outstanding common shares on the basis of one post-consolidation common share for every 10 pre-consolidation common shares. The name of the Company will not be changed in conjunction with the proposed share consolidation.

The special resolution approving the proposed share consolidation received the affirmative votes of approximately 93% of the common shares of the Company cast at the Special Meeting. The special resolution authorizes the Company's board of directors to determine, in its sole discretion, whether and when to implement the share consolidation within six months of the special resolution. Implementation of the proposed share consolidation is also subject to the acceptance of the TSX Venture Exchange.

About Welichem Biotech Inc.

Welichem Biotech Inc. is a publicly-traded biotechnology company developing therapeutic drugs in the fields of autoimmune diseases and cancer. For a more complete business and financial profile of the Company, interested parties are encouraged to visit the Company's website, www.welichem.com.

ON BEHALF OF THE BOARD
Tan Xiangdong, Chairman of the Board

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. This press release contains forward-looking statements that include our belief as to the effects of the proposed share consolidation. Certain risks and uncertainties such as our ability to successfully complete the share consolidation could cause the Company's actual results to differ materially from those in the forward-looking statements.

%SEDAR: 00021386E